Home / Tag Archives: stock trading (page 2)

Tag Archives: stock trading

Triple-bottoms play for $NUGT

Take a look at the daily chart below.


Can you see the “triple-bottom” with a slight angle to the upside on the trendline?  This triple-bottoms can only be confirmed if price does not penetrate the low of Sept 13th.  For me, this represents a low risk trade.  I bought a starter position today with a GTC hard stop below the Sept 13th low.  Let’s see if I can hit the ball over the park “again” this time.

My 2 cents

Comments »

$KNDI – an alternative “catch-up” play to $TSLA

$KNDI has entered the EV market in China by forming a joint venture with a subsidiary of China’s #1 manufacturer of passenger vehicles, Geely Holdings (GELYF) (HK.0175) to form Zhejiang Kandi Electric Vehicles Investment Co. in Zhejiang Province, China.

There are plenty of due diligences “analyses” that cover both the pro and con of investing in $KNDI.  Take your pick.  I’ve picked mine and is currently long on $KNDI.

If you follow my twitter activities, you know I’ve been accumulating $KNDI since last Wednesday.

Yes, I know what you are going to say, “What?  Another Chinese company?  You’ve got to be kidding!”

I kid you not! (grin)

Take a look at the daily chart below:


Price has taken out the 79 SMA today as well as the upper band of the Bollinger Bands.  These two breakouts combined together formed a powerful momentum in my book.

Take a look at the weekly chart below:


Look at that V-shape bounce from both the 79 SMA and 89 XMA.

Fundamentally speaking, here is a good read from someone who has done a far better job researching this company:

Kandi Technologies: Exceptional Strategy For China From An Urban Planning View

By all mean, read up on the comment section to learn both sides of the arguments b/w the bull and bear.

In my opinion, this is a highly speculative stock that has the potential to play catch-up to $TSLA if you’ve missed that train.

My 2 cents.


Comments »

Go! Go! $GOGO

I think this is going to be another winner from The Fly.

Fundamentally speaking here is why I like this stock:

Aircell Introduces In-Flight Calling and Texting for Personal Smartphones

Gogo Text & Talk service allows passengers to call and text via Wi-Fi in flight, using their own smartphone and mobile number
Company also adds voice capabilities to existing Gogo Biz service

BROOMFIELD, Colo., Aug. 28, 2013 /PRNewswire/ — Aircell (GOGO), a leading provider of in-flight connectivity equipment and services to the business aviation market, announces that its Gogo Biz service will expand to include voice capabilities, beginning October 1st. Gogo Biz was originally launched in 2009 as an Internet-only service in the business aviation market.

Do you remember how expensive it is to use the phone from the airplane?  It is almost like a legal highway robbery.  Now, if I’m paying for the internet service inside the airplane, I like the idea that I can use my smartphone to “call” someone without having to pay thru my nose with the airplane phone.   In other words, I don’t mind paying for the internet cost as long as I can also use internet voice capabilities to call someone using my smartphone. We are not talking about Skype phone here, we are talking about using your own mobile phone number. Below is an excerpt from the press release…

Gogo Text & Talk. Your Own Smartphone, Your Own Number
Gogo Text & Talk is an exclusive new service that allows passengers to use their own smartphones for calling and texting in flight – with their own mobile number.

I believe once $GOGO turns on this voice capabilities starting October 1st, revenues stream will double.

Take a look at the daily chart below:


I can see a cup and handle break out in the making.  I’m going on a preemptive strike by buying $GOGO today looking for an “imminent” breakout soon.

Oh yeah, thanks to The Fly for making me aware of $GOGO.

My 2 cents.



Comments »

Can $CERS break out of its long-term resistance?

I’m betting that it will.

Take a look at the monthly chart below:


Currently, price action is bumping against the 89xma as well as the resistance that go way back to the high of April 2004.  However, from the look of it, price action has been “grouping” upward on a monthly basis recently.  I’m sure all it takes now is a little nudge and price action will just explode skyward.  Skyward!  Uh Oh!  You’ve caught me using the “pumping” word…

Anyway, my interpretation is that the chart looks bullish.

Below is the weekly chart:


This week bar is very strong which may be setting up the stage for next week big push to break out of the monthly resistance.

Below is the daily chart:


See how it bounces off near the 79 sma and the 89 xma?  The 5 sma is now crossing over the 15 sma.  All of these technical signals just give me more confidence to add more today.

Fundamentally speaking, instead of rehashing of what others have done, I’m going to paste an excerpt from (gawd forbids) a contributor in Seeking Alpha…

GZ: Cerus Corp. (CERS) is a very interesting company. It developed a blood pathogen inactivation system, called INTERCEPT, for all three products derived from blood donations – platelet concentrates, plasma and red blood cell concentrates. A key milestone that the company recently reported was an agreement with the FDA allowing it to file for premarket approval (PMA) for the platelet concentrates in the U.S. without having to do another phase 3 trial. Assuming an approval, this shortens the time to commercialization by one to two years.

Notably, the company is already selling its INTERCEPT Blood System in quite a few countries, mainly in Europe. All of Switzerland uses the product for platelet concentrates. Much of France uses the system. A number of centers in Germany, Belgium and other countries use it. INTERCEPT is a revenue-generating product for an unmet need because emerging pathogens, viruses in particular, might be penetrating the blood supply, while bacterial contamination of platelet concentrates, though rare, still kills patients.

Once the authorities that regulate the blood supply look at INTERCEPT, it becomes a no-brainer. However, these are typically bureaucratic government organizations, and sometimes it takes a crisis, as it did in Switzerland with the untimely death of a child who was administered platelet concentrates contaminated with bacteria, to get INTERCEPT approved and used.

There’s no real blockbuster here in the sense that the company will end up with billions in revenue from this product after it gets more approvals. But Cerus is a relatively risk-free and an incrementally positive investment that I see growing steadily year over year. I think approval in the U.S., possibly in the second half of next year, would be a strong catalyst for the stock.

TLSR: Could these systems be used in the field, such as in developing countries, as easily as they could be used in a modern clinic?

GZ: Yes. Basically, INTERCEPT is a kit with bags for treatment and for storage of the final product, and what’s called an illuminator, an ultraviolet light that catalyzes the reaction between the additive and the DNA of pathogens, which are prevented from replicating. All that is needed is an electrical supply and other basic equipment for blood handling-refrigeration for plasma and red blood cells. Platelets are kept at room temperature. The really big markets are the big blood centers-the American Red Cross, the New York Blood Center and others.

This time around, I’m going to “try” to sit on this position for a longer-term hold…

My 2 cents.


Comments »

Cup and Handle breakout for $AMRN

So much for coming in this morning with load of cash on hand.  I’m just thankful that there is no “surprise” news on $AMRN that I’ll be deprived of a reasonable re-entry from zero position.  As luck will have it, I only have to pay a small premium to buy back my core position plus more for swing trade.

Take a look at the daily chart below:


I like the fact that price action has taken out the high of July 2013 at $6.20.  On top of that, price action also took out the 79sma as well as the 89xma.  If price action can maintain momentum, we may have a rally toward the October FDA Advisory Committee meeting that most investors (myself included) are expecting a slam-dunk “clear ahead” for the December FDA decision on approving Vascepa for the mid-trig (200-500) population.  Of course, you also have Adam Feuerstein who holds the opposite opinion of $AMRN getting a nod from the FDA. Who do you believe?

Don’t believe anyone; but believe only on your own research. Read up on the FDA approval process if you are not familiar with it.  You will find that it takes a very long and expensive road for any company to get a prescription drug approved by the FDA.  $AMRN has come a long-way and it is now knocking on the door of FDA for the mid-trig (200-500) level.  Have you seen any other competitors offering the same thing?  Even if there are, they are still a long way before knocking on FDA door. Recent purchase of Omthera by AstraZeneca ($AZN) is an example.

Yes, I’ve been on the wrong side of the track for quite a while with $AMRN but I believe the road is now heading on the right direction. Nevertheless, at this point, I’m watching $AMRN as an intermediate-term trader instead of a die-hard buy and hold investor. In other words, I’m not married to the stock so to speak.

My 2 cents.

Comments »

The only time you can be wrong and still not lose money

is when you are in cash.

I’m betting that the market is going to correct starting later today or next week and I can be totally wrong.  And to stand by my bet, I’ve raised my cash level to 67% as of now.

Why am I making such a bet?

Take a look at the daily $SPY chart below:


I asked myself what is $SPY “not” doing?

It is not taking off in a big way to follow up with yesterday momentum.  Regarding yesterday momentum up day, did you notice that the volume was less than the volume of the previous down day?

It is very possible that we are looking at a dead cat bounce and again, it is possible I’m very wrong.  Some will say we are bouncing right off the 79 sma line.  That is very true too.  As much as I can see the bounce, the underlying lower volume behind the bounce bothers me.

So, what’s wrong with my being wrong?


I’ll just have to start nibble back in next week if the market continues to head skyward.

On the other hand, I could be looking for bargain hunting.

Either way, I’m feeling quite peaceful with a high level of cash as of now.

My 2 cents.

Comments »

Shifting with the wind- from the gale of $NUGT to the gust of $INO

It was quite a strange morning.  The leaves were wavering a little harder, the fallen leaf flew a little further out, and most important of all, my eyes were bombarded by flying tiny debris such that I had to squint to see what kind of wind was blowing my way…

Being in a twilight state of consciousness, the winds formed into the shape of an animal… and the horns looked familiar… OMG! they were bull’s horns.  The image was like a slow motion replay of a bull stampede scene  you saw in Lone Ranger movie.  Because they were winds, the bulls ran right through me as if I was merely a shadow of the nearby tree.  From my vantage point, I could see the burned mark on one of the bull.  It was branded at $INO.

The gust of $INO was getting ready to stampede!  I immediately checked the price.  It was printing over $1.30 by the time I checked the screen.  I could sense this move had a malevolent tone and the desperation in the price action was quite palpable.  Without hesitation, I clicked on the buy button again, again, again, and again.  The fills were completed in a stair-step fashion with each fills higher than the others.

Then I wait.

Price action did not falter.  Not only did price action take out the yesterday high, it took out $1.50 resistance.  And for that, I added more.

By day end, the gust of $INO has taken my position to $1.68.

The interesting part about my hitching the gust of $INO today was that I was just getting off the gale of $NUGT.  $NUGT’s gale had taken me for a ride from the bottom of the valley to the top of mountain where I could see the $100 roll dangling outside my reach.  There were magic involved for I had started off at low $5.xx at the beginning of the ride.  Out of nowhere, the ETF master flipped the wand and I was seeing $98.xx!  As I reached out to the $100 roll, the gale suddenly dissolved into a tepid breeze and I was left standing at $89.6x.  So much for the $100 roll.

Without missing a step, I’m now riding the gust of $INO.  How far can I ride this gust?  Will it even head in the same direction tomorrow?  I sure do hope so.  I could feel the energy.  I could hear the crying.  I believed they were the cry of the shorts being squeezed.

Holy Cow!  The Gust of $INO might just continue to fly straight ahead on the back of the short-squeezed runaway…  YEOWWWWEEE! The pain!  The pain!” uttered the shorts…

My 2 cents…


Comments »

$NUGT Post-split Revisit

As The Fly used to say, “going for the $100 roll…”

Well, that is what I like to say for $NUGT as well.  After the 1 for 10 reverse split, price action continues to look bullish.

Instead of reading $9.78 on the price chart, now I’m reading $97.84.  Whoa!  It is going for $100!

I guess there is a nice sound to it.  So, I’ll have the ETF master to thank for the reverse split.

Heeeeerrrrrrreeeeeeee comes $1 0 0!

Ok, kidding asides, take a look at the daily chart below:


Today green bar is a good sign after two days of correction.  Next resistance is high of two days ago at $103.90.  I say price can take that out before the week is over.  Next target after that is $124.20.

Below is the 5m chart:


Isn’t it a beauty to see a persistent intra-day bullish trend?

Coming into the morning, I only had a small starter position, after seeing price action took off to the upside after open, I bought back in full-size looking for the $100 roll…

Good luck if you are already in $NUGT.

My 2 cents.


Comments »

David & Goliath, the battle of DNA Sequencing

Why is $PACB continuing to show strength?  What is the fundamental driver here?

First off, the problems and issues that brought $PACB’s DNA Sequencer down since their IPO have been addressed and remedied according to their latest earnings report update.  Customers are beginning to come back.

However, I believe the latest price upward momentum may have to do with the latest find:

Scientists Assess Error Modes in Sequencing Platforms and Find SMRT Sequencing ‘Least Biased’

Monday, August 19, 2013

Scientists Assess Error Modes in Sequencing Platforms and Find SMRT Sequencing ‘Least Biased’

A paper from scientists at the Broad Institute reports a rigorous study of bias across all major sequencing platforms. In “Characterizing and measuring bias in sequence data,” published in Genome Biology, lead author Michael Ross and his colleagues report that SMRT® Sequencing on the PacBio® sequencer is the “least biased” in coverage of all the technologies studied.

The authors assessed sequences for coverage bias, or uniformity of read distribution, and error bias, or incorrect call at a given position. For coverage bias, they report that PacBio performed best in extreme GC content (both GC-rich and GC-poor) and suggest this may be related to the lack of an amplification step in the sequencing process. Regarding error bias, the scientists describe shifting error rates based on genome sequence; GC-rich or homopolymer regions, for example, tended to change the rate of errors for each platform. “In general, the sequence context dependence of error rates varied considerably from technology to technology,” they write.

Ross et al. note that each platform’s bias rate changes with technology development, but note that at the time of their work, “single-molecule data from Pacific Biosciences” had “the clear edge.”

Below is the actual report from Genome Biology:

Characterizing and measuring bias in sequence data

Michael G Ross*, Carsten Russ, Maura Costello, Andrew Hollinger, Niall J Lennon, Ryan Hegarty, Chad Nusbaum and David B Jaffe

Genome Biology 2013, 14:R51   doi:10.1186/gb-2013-14-5-r51
Published: 29 May 2013

DNA sequencing technologies deviate from the ideal uniform distribution of reads. These biases impair scientific and medical applications. Accordingly, we have developed computational methods for discovering, describing and measuring bias.

We applied these methods to the Illumina, Ion Torrent, Pacific Biosciences and Complete Genomics sequencing platforms, using data from human and from a set of microbes with diverse base compositions. As in previous work, library construction conditions significantly influence sequencing bias. Pacific Biosciences coverage levels are the least biased, followed by Illumina, although all technologies exhibit error-rate biases in high- and low-GC regions and at long homopolymer runs. The GC-rich regions prone to low coverage include a number of human promoters, so we therefore catalog 1,000 that were exceptionally resistant to sequencing. Our results indicate that combining data from two technologies can reduce coverage bias if the biases in the component technologies are complementary and of similar magnitude. Analysis of Illumina data representing 120-fold coverage of a well-studied human sample reveals that 0.20% of the autosomal genome was covered at less than 10% of the genome-wide average. Excluding locations that were similar to known bias motifs or likely due to sample-reference variations left only 0.045% of the autosomal genome with unexplained poor coverage.

The assays presented in this paper provide a comprehensive view of sequencing bias, which can be used to drive laboratory improvements and to monitor production processes. Development guided by these assays should result in improved genome assemblies and better coverage of biologically important loci.

Enough about the fundamental, take a look at the weekly chart below:


While there is a beauty in seeing the nice rally today, price action needs to take out the nearest resistance at $4.00 so it can move on to the next target at $5.27 which was the high made in 2/17/2012.  Since both resistances are more than a year old; breaking out of these resistances can only mean that the power behind the move is substantial and strong; otherwise, price action will fall apart after touching the resistance(s).

Giving the new development in how much better $PACB’s DNA Sequencer is due to its being the “least biased”, I’m betting that price can cut thru those resistances like hot knife against butter.

Needless to day, I added more $PACB today due to strong morning price action.

My 2 cents.


Comments »

V-shape $CORN anyone?

Anyone interesting in taking a bite of a V-shape $CORN?

I’m game for it.

Take a look at the weekly chart below:


$CORN broke out of last week high and I bought in a decent size position for a possible V-shape bounce.

I like to see $CORN hit the target of $43 in the near future soon; otherwise, it won’t be called V-shape.

Below daily chart shows a decent breakout of the last 5 trading days.


Fundamentally speaking, Dry Weather and Abandoned Land Help Bolster Corn ETF.

The caveat of trading agriculture commodity is that its price action is subjected to extreme volatility due to weather condition.  On the other hand, price can stay on trend due to persistent fundamental reason.

My 2 cents.

Comments »